Health
“Scientists found that the experimental compound ISRIB improved memory performance in mice with learning difficulties or brain injuries by up to 70% within 48 hours." (Caption: "Within only two days, the animals demonstrated up to 70% better memory performance when navigating routes, identifying locations, and completing complex tasks."…”
Plain restatementIn published research, the experimental compound ISRIB produced up to a 70 percent improvement in memory performance within 48 hours in mice with cognitive impairment or traumatic brain injury, as reported by a February 2025 ScienceDaily article.
General information only - not medical advice.
This post cites a ScienceDaily article as its source, but that article is about a completely different experimental drug called GL-II-73, not ISRIB. ISRIB is a real compound and real studies did find it restored memory in mice with brain injuries and in old mice, published in PNAS in 2017 and eLife in 2020. However, no study or report could be found that says ISRIB improved memory by up to 70 percent, or that it did so within 48 hours. The actual experiments gave mice injections on three consecutive days and tested memory days to weeks later, and the headline finding was that the benefit lasted after dosing stopped, not that it appeared in two days. All of the memory evidence is in mice. The drug developed from ISRIB for humans, fosigotifator, failed a late-stage trial in ALS in January 2025 and the development partnership behind it ended in November 2025. ISRIB is an injectable laboratory compound, not a supplement, so the post's offer of a supplement guide has no connection to this research.
[drifted from the evidence:] Scientists found that the experimental compound ISRIB [drifted from the evidence:] improved memory performance in mice with [drifted from the evidence:] learning difficulties or brain [drifted from the evidence:] injuries by [drifted from the evidence:] up to 70% within 48 hours." (Caption: "Within only two days, the animals demonstrated up to 70% better memory performance when navigating routes, identifying locations, and completing complex tasks." Source cited: "ScienceDaily, [drifted from the evidence:] Drug Shows Rapid Improvement in Memory and Cognition," https://www.sciencedaily.com/releases/2025/02/250204141840.htm)
[added by the neutral restatement:] In published research, the experimental compound ISRIB [added by the neutral restatement:] produced up to a 70 percent improvement in memory performance [added by the neutral restatement:] within 48 hours in mice with [added by the neutral restatement:] cognitive impairment or [added by the neutral restatement:] traumatic brain [added by the neutral restatement:] injury, as reported by [added by the neutral restatement:] a February 2025 ScienceDaily [added by the neutral restatement:] article.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- ISRIB is a real experimental compound, and it was tested in mice with brain injuries and with age-related cognitive decline.
- Published peer-reviewed studies did report improved memory performance in brain-injured mice and in old mice after ISRIB treatment compared with controls.
- The described mechanism is broadly correct: ISRIB inhibits the integrated stress response, which is elevated after injury and with aging.
- The description of potential future applications, including Alzheimer's disease, post-injury memory loss, and stress-related cognitive problems, reflects how researchers have framed the work as a possibility, not a demonstrated result.
- Fabricated or untraceable statistic: the "up to 70%" figure appears in no located study, press release, or reputable report on ISRIB. The published outcome measures are maze error counts, not a percentage memory improvement.
- Date and context mismatch amounting to source misattribution: the cited ScienceDaily link is about GL-II-73, a different compound from a different institution. The post attributes ISRIB findings to an article that never mentions ISRIB.
- Temporal distortion: the claim's "within 48 hours" inverts the actual finding. Dosing was three consecutive days and the striking result was that benefits persisted days to weeks after treatment stopped.
- Species extrapolation by framing: calling ISRIB "one of the most exciting discoveries in modern neuroscience" for "memory enhancement" without stating that the entire efficacy record is in mice, and that the human clinical program built on it failed.
- Omitted qualifier: no mention that the ISRIB-derived drug fosigotifator failed a Phase 2/3 trial in January 2025 and that the development partnership ended in November 2025.
- Marketing as evidence: the post uses the research as a hook for a supplement guide. ISRIB is not a supplement and no supplement replicates it.
- The origin of the "70%" number could not be traced. It circulates in Substack and social aggregator posts but no underlying document producing it was found. It may be an invented figure or a garbled rendering of some unrelated statistic.
- Whether any single ISRIB paper reported a behavioral readout at approximately 48 hours could not be fully ruled out, because the search session ended before the 2013 Sidrauski eLife paper's exact testing timeline could be retrieved and read in full. Background knowledge, flagged as model knowledge and not a retrieved source, is that the 2013 work dosed around training and tested memory days later, which still would not support a "70% in 48 hours" framing.
- Whether the post author misread a different article or deliberately attached a mismatched link cannot be determined.
The specific source the post cites does not describe ISRIB at all. The February 4, 2025 ScienceDaily item at the exact URL in the caption is about a different experimental compound: it reports on GL-II-73, an experimental drug studied by the Centre for Addiction and Mental Health, described as having potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. It is a pre-clinical mouse study of a different molecule by a different research group. Real ISRIB research does exist and is substantial. Chou et al. (PNAS, 2017) reported that ISRIB reversed cognitive deficits induced by traumatic brain injury in two different injury mouse models, focal contusion and diffuse concussive injury, and that ISRIB corrected TBI-induced memory deficits when administered weeks after the initial injury. In the radial arm water maze, sham and ISRIB-treated injured animals learned the escape platform location and made fewer errors during a memory test conducted seven days after training, thirty-seven days post-injury. A separate eLife paper reported that ISRIB treatment reverses ISR activation in the brain and reverses spatial memory deficits and ameliorates working memory in old mice, using a treatment paradigm of daily injections on three consecutive days, with old mice treated with ISRIB one week before testing making significantly fewer errors than vehicle-treated controls. No located source, primary or secondary, reports a "70 percent" improvement figure or a "within 48 hours" result for ISRIB. The published designs measure errors in maze tasks across training blocks, not a single percentage improvement in "memory performance." The scientifically notable feature of these studies is the opposite of a 48-hour effect: effects persisted long after a brief dosing course. A UCSF researcher noted that ISRIB's half-life is less than a day, making the persistence of its effects intriguing and suggesting it may induce some durable change in the brain. On human relevance: the ISRIB-derived clinical candidate has not succeeded. Calico licensed ABBV-CLS-7262 from Peter Walter's laboratory at UCSF, the group that published the ISRIB papers, and began a Phase 1 safety study in people with ALS in September 2021. In January 2025 AbbVie and Calico announced the drug had failed a Phase 2/3 trial in ALS, and in November 2025 AbbVie ended its partnership with Calico. ISRIB itself showed promising results in mouse models of brain disorders but efforts to develop a drug based on it had failed as of 2025.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.
Ask this case
Answers come only from the case file above; nothing is added.
Does the ScienceDaily article cited in the post actually mention ISRIB?
No. The exact article linked is about a different experimental compound called GL-II-73, studied by the Centre for Addiction and Mental Health in a mouse model of Alzheimer's disease. It does not discuss ISRIB at all.
Is there any real research on ISRIB and memory?
Yes. Peer-reviewed studies published in PNAS in 2017 and eLife in 2020 found that ISRIB improved memory performance in mice with traumatic brain injury and in old mice, compared with untreated controls. All of this evidence comes from mouse studies, not humans.
Where does the '70% improvement within 48 hours' figure come from?
The investigation could not trace this figure to any study, press release, or report on ISRIB. The real studies measured maze errors, not a percentage improvement, and dosing was given over three consecutive days with memory tested days to weeks later, not within 48 hours.
Has ISRIB or a related drug been tested in humans?
A clinical candidate developed from ISRIB, called fosigotifator, was tested in people with ALS. It failed a Phase 2/3 trial in January 2025, and the companies developing it ended their partnership in November 2025.
Does this research have anything to do with supplements?
No. ISRIB is an injectable laboratory compound used in animal research, not a supplement, and the case file found no connection between this research and any supplement product.